DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show

DPX-Survivac Shows Promise in Advanced OC, Early Phase 2 Data Show
Treatment with IMV's cancer vaccine DPX-Survivac, combined with intermittent low-dose cyclophosphamide, continues to show promise in women with recurrent, advanced ovarian cancer, updated results from a Phase 1/2 trial show. Fifteen of the first 19 patients examined for efficacy experienced some level of clinical benefit from the combo treatment, with benefits lasting over six months in seven of them, according to updated data from the DECIDE1 trial (NCT02785250). Treatment was well tolerated, with most side effects being mild to moderate reactions at the injection site. “We are highly encouraged by the data from DECIDE1, which shows that DPX-Survivac immunotherapy was well tolerated and achieved sustained clinical activity in advanced and recurrent ovarian cancer," Joanne Schindler, MD, chief medical officer at IMV, said in a press release. "This is a particularly significant observation in heavily pre-treated patients, for whom remain tremendous unmet need and limited options beyond single-agent chemotherapy, which generates responses in just 12% of patients, with short duration and severe adverse effects,” Schindler said. DPX-Survivac is a new class of T-cell immunotherapy designed to stimulate the immune system to t
Subscribe or to access all post and page content.